Clinical trials: Cholesterol, LDL
Elevated LDL Cholesterol
A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol
This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of…
- Trial name
- NCT01004705
- Testing
- Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ferrer Internacional S.A.
Familial Hypercholesterolemia
A Registration Study for Familial Hypercholesterolemia in Taiwan
Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism, transmitted in an autosomal dominant manner and clinically characterized by elevated levels of total cholesterol (TC) and low-density…
- Trial name
- NCT03152656
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
High LDL-cholesterol Levels
Red-fleshed Apple as a Novel Anthocyanin-biofortified Food to Improve Cardiometabolic Risk Factors.
The primary aim is to evaluate the added health value of the presence of anthocyanins in the redlove apple, versus a green apple with a similar matrix, on cardiometabolic risk, and compare the matrix effect on the bioavailability…
- Trial name
- AppleCor (NCT03795324)
- Testing
- Redlove Apple intervention, Green Apple intervention, Aronia drink intervention
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- University Rovira i Virgili
Healthy Volunteers
Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers
The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.
- Trial name
- NCT03118583
- Testing
- 300 mg/day of dietary supplement containing carrageenan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol
Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
This Open-label, randomized clinical trial evaluates the comparative efficacy and safety of dual versus triple lipid-lowering therapy using rosuvastatin, ezetimibe, and bempedoic acid in patients with type 2 diabetes mellitus and…
- Trial name
- NCT07255820
- Testing
- Rosuvastatin + Ezetimibe, Bempedoic Acid + Ezetimibe, Rosuvastatin + Ezetimibe + Bempedoic Acid
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Bahria University
Statin Therapy, Statin Adverse Reaction
DESIFOR-EXPAND (MHIF)
The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
- Conditions
- Statin Therapy, Statin Adverse Reaction, Statin
- Trial name
- NCT06804980
- Testing
- Rosuvastatin (Crestor)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Minneapolis Heart Institute Foundation
Hypercholesterolemia
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
- Trial name
- NCT02072161
- Testing
- ETC-1002, Statin Therapy
- Where
- 40 sites in United States
- Volunteers
- 133 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypercholesterolemia
Evaluation of Crestor® (Rosuvastatin) in Daily Practice
This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia.
- Trial name
- NCT00837083
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Ischemic Stroke
Atherogenic Lipoproteins in Ischemic Stroke
Apolipoprotein B (apoB) levels (which encompass all atherogenic lipoproteins, including LDL), Lp(a) levels, and carotid IPH are associated with both first-ever and recurrent ischemic stroke.
- Trial name
- AGELESS (NCT05090878)
- Where
- 2 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University Hospital, Basel, Switzerland
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
- Trial name
- CLEAR Serenity (NCT02988115)
- Testing
- bempedoic acid
- Where
- 67 sites in United States, Canada
- Volunteers
- 345 people
- Sponsor
- Esperion Therapeutics, Inc.
Foot Ulcers, Arteriosclerosis Obliterans
HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)
Diabetic foot (DF) is a common, severe and costly complication of diabetes. DF is underlied by neuropathy, atherosclerosis of distal arteries and infection, which result in tissue ulcers and necrosis.
- Conditions
- Foot Ulcers, Arteriosclerosis Obliterans, Diabetes Mellitus
- Trial name
- HADIF (NCT01518205)
- Testing
- LDL-apheresis
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Universita di Verona
Atherosclerosis, Cardiovascular Diseases
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
The INTENSITY-LOW study aims to answer if there are any limits to LDL reduction in relation to benefitting vascular health from a mechanistic viewpoint, and therefore potentially limitations to primary prevention in healthy…
- Trial name
- NCT03273972
- Testing
- Written Informed Consent, Inclusion/Exclusion check, Full Clinical Chemistry and Haematology Bloods
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Lipids, Lipid Metabolism
RISSCI-1 Blood Cholesterol Response Study
Raised blood cholesterol (also referred to as blood LDL-cholesterol) is a major risk factor for developing heart disease. Dietary saturated fat is recognised as the main dietary component responsible for raising blood…
- Conditions
- Lipids, Lipid Metabolism, Healthy
- Trial name
- RISSCI-1 (NCT03270527)
- Testing
- High SFA diet (Diet 1), Low SFA diet (Diet 2)
- Where
- 2 sites in United Kingdom
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Cardiovascular Diseases
Effect of a Black Garlic Extract on Cholesterol LDL Levels
One of the most characteristic components of the Mediterranean diet is garlic (Allium sativum L.), food to which has been attributed protective properties against cardiovascular diseases (CVD).
- Trial name
- ESACTIVO (NCT04010565)
- Testing
- Aged black garlic extract
- Where
- Spain
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Technological Centre of Nutrition and Health, Spain
Hypercholesterolemia
Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)
The purpose of this study is to compare the efficacy and safety of rosuvastatin with simvastatin and atorvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia
- Trial name
- SOLAR (NCT00654173)
- Testing
- Rosuvastatin, Simvastatin, Atorvastatin
- Volunteers
- 4,444 people
- Sponsor
- AstraZeneca
Dyslipidemia
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.
- Trial name
- NCT00504829
- Testing
- LCP-AtorFen, atorvastatin, fenofibrate
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Veloxis Pharmaceuticals
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
This clinical trial has two parts. In Part A, the goal is to learn about the safety and tolerability of COR-2003 when it is given alone.
- Trial name
- NCT07858019
- Testing
- COR-2003, COR-1004 + COR-2003
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Cardiovascular Diseases, Hyperlipidemias
Supplementation of Oil Palm Phenolics to Healthy Participants
Our previous study has found that oil palm phenolics (OPP) supplementation at 9 grams per day is safe for consumption. An interesting observation was reported where the consumption of OPP showed significantly lower total and LDL…
- Conditions
- Cardiovascular Diseases, Hyperlipidemias, Hypercholesterolemia
- Trial name
- SPIRAL (NCT04164446)
- Testing
- Oil Palm Phenolics
- Where
- Malaysia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Hypercholesterolemia, Heterozygous Familial
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Primary objective: Determine whether mipomersen (ISIS 301012) significantly reduces atherogenic lipid levels in patients with severe heterozygous familial hypercholesterolemia (severe HeFH), defined as low-density lipoprotein…
- Trial name
- FOCUS FH (NCT01475825)
- Testing
- mipomersen sodium 200 mg, mipomersen sodium 70 mg
- Where
- 113 sites in United States, Argentina and 28 more
- Volunteers
- 309 people
- Sponsor
- Kastle Therapeutics, LLC